Notably, owing to its promising clinical trial outcomes, it has gained FDA approval as a therapeutic option for myelodysplastic syndrome (MDS).[246] Ligufalimab (AK117) is a novel CD47 antibody that hinders the growth of blood and solid tumor cell lines. Here, CD47 is linked to myelodysplastic syndrome.